Drug intelligence / Profile preview

Licartin + CIK

Development stage: Unknown
Lead developer: Chengdu Huasun Biotechnology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intra-arterial, Intravenous

Overview

Licartin + CIK is a combination therapy consisting of Licartin (Iodine-131-labeled metuximab), a radiolabeled monoclonal antibody targeting CD147 (basigin) antigen expressed in hepatocellular carcinoma (HCC), and cytokine-induced killer (CIK) cells, which are ex vivo expanded immune effector cells with both T cell and natural killer cell properties. Licartin delivers targeted radiotherapy to tumor sites via the CD147 antigen, causing direct cytotoxicity through radiation. CIK cells exert antitumor effects by recognizing and killing tumor cells in an MHC-unrestricted manner through mechanisms involving perforin/granzyme-mediated cytotoxicity and secretion of pro-inflammatory cytokines. The combination aims to enhance antitumor efficacy by integrating targeted radiotherapy with adoptive cellular immunotherapy. This approach has been investigated primarily for advanced or recurrent hepatocellular carcinoma.

Brand names: Licartin
Other names: Iodine[131I] metuximab + cytokine-induced killer cells131I-metuximab + CIK cells

Targets

BSG (Basigin)

Beyond the preview

Go deeper on Licartin + CIK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Licartin + CIK.

Explore the full profile